on behalf of the EUROASPIRE IV investigators Abstract Aims: Chronic kidney disease (CKD) is associated with the development and progression of coronary heart disease (CHD), in addition to classic cardiovascular risk factors. We analysed the prevalence of CKD in CHD patients from 24 European countries in the ambulatory setting and in a preceding hospital stay for CHD (index). Methods and results: A total of 7998 EUROASPIRE IV participants (median 65 years of age, 76% male) attended a study visit 6-36 months after the index hospitalisation. CKD was classified according to stages of estimated glomerular filtration rate (eGFR) and albuminuria (urinary albumin/creatinine ratio). In stable CHD conditions (study visit), 17.3% had CKD (eGFR <60 mL/min/1.73 m 2 ) with variation among participating countries (range 13.1-26.4%). A further 12% presented with preserved eGFR but significant albuminuria. During the hospital stay due to a coronary event, impaired kidney function was observed in 17.6% (range 7.5-38.2%). Risk factors for impaired kidney function included older age, female gender, classic cardiovascular (CV) risk factors, details of CHD history and congestive heart failure (multivariate regression). Of all patients, 38.9% had declined, 31.3% were stable and 29.8% had improved kidney function between hospital discharge and the study visit, dependent on age, gender, CV risk factors, CHD history and cardiac dysfunction (multivariate regression). Conclusions: Every fifth CHD patient had CKD, while every tenth exhibited albuminuria as the sole indicator of kidney damage. These subjects are at increased risk of progression of CKD and CHD complications. After hospital stays due to CHD, there is potential of recovery of kidney function, but our findings underline the importance of identifying patients who are at high risk of developing CKD in order to counteract disease progression.
Introduction
Patients with coronary heart disease (CHD) are at high risk of subsequent cardiovascular (CV) events. 1 Even if clinical practice guideline recommendations are followed in secondary prevention, including modification of lifestyle and behaviour by quitting smoking, counteracting overweight/obesity and increasing physical activity, and by adequate control of blood pressure, low-density lipoprotein (LDL)-cholesterol and hyperglycaemia, 2 there is a residual risk of morbidity and mortality among such patients. Over the last decades, evidence has accumulated that chronic kidney disease (CKD), an important risk modifier in CHD 3 associated with CHD progression, 4, 5 worsening of heart failure 6 and an increased risk of hospitalisation and mortality, 4, 7 may be a link to the remaining risk. Both CHD and CKD share similar pathogenetic pathways such as arteriosclerosis/atherosclerosis and chronic inflammation. 8, 9 CKD itself is common in the Western world and is associated with an aggravated risk of mortality and morbidity when compared to the healthy population. [10] [11] [12] CKD disposes the patient to complications and a worse clinical course in hospital stays of various causes, including admissions for CHD. 13 On the other hand, acute cardiac events can directly affect renal function, leading to acute kidney injury (AKI), which itself is an important risk factor of both the development and progression of CKD, 14 the progression of CHD and impaired outcomes in CHD. 15 Despite these prognostic implications, comprehensive data on the contemporary prevalence of CKD in CHD patients across Europe are lacking, as well as data on impairments in kidney function during hospitalisation for CHD.
The present study investigated the prevalence and characteristics of CKD in stable CHD patients using data from the EUROASPIRE IV study in 24 European countries. Current nephrology (Kidney Disease: Improving Global Outcomes [KDIGO]) recommendations for CKD classification were applied, 8 and variations of CKD rates among participating countries were investigated. Moreover, the proportion of impaired kidney function at a hospital stay due to CHD is reported, together with changes in kidney function between the hospital stay and the study visit at least 6 months after hospital discharge.
Methods

Patient population
The study design and methodology of the fourth European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE IV) survey have been published previously. 16 Figure S1) . Within each country, a geographical area (>0.5 million people) was selected, with at least one hospital offering interventional cardiology and cardiac surgery and one or more acute hospitals admitting patients with MI and myocardial ischaemia. Within these centres, all hospitalised patients meeting the inclusion criteria were identified from the hospital's patient management systems and invited to participate in the study. EUROASPIRE IV addressed lifestyle changes and control of classic CV risk factors in clinical practice in CHD patients. 16 The study also focused on previously undetected diabetes and dysglycaemia, 17 as well as on renal impairment. Local ethics committees approved the study in each country and all patients provided written informed consent.
Data collection
Detailed data were collected at the study visit regarding all aspects of secondary prevention, including medical history, medication, behaviour and control of risk factors; these also included standardised measurements of blood pressure, weight, height and carbon monoxide (CO) in exhaled air. 16 Blood samples were drawn in a fasting state, processed immediately and stored at À80 C on site. After completion of recruitment, samples were shipped to the central EUROASPIRE IV laboratory (Laboratory of Analytical Biochemistry, National Public Health Institute, Helsinki, Finland), where serum creatinine (SCr), lipid levels and HbA1c were measured. SCr analysis was performed in a clinical chemistry analyser (Abbott Laboratories, Abbott Park, IL, USA) and determined enzymatically using commercial reagents from Sentinel (Milan, Italy) (coefficient of variation 1.1 AE 0.1%, systematic error (bias) 0.4 AE 1.0%). The urinary albumin/creatinine ratio (ACR) was measured locally at each study centre as requested by the EUROASPIRE IV protocol. Study participants also consented to a retrospective chart review of the index hospital stay in order to obtain information on the index event, risk factors, medications and clinical measurements, including SCr at admission (i.e. the first measurement in the patient record) and ACR (Supplementary Figure S1 ).
Definitions
Kidney function was classified according to KDIGO (Figure 1 ), while CKD glomerular filtration rate (CKD-G) stages were defined by applying the CKDEpidemiology Collaboration (CKD-EPI) equation in order to calculate the estimated glomerular filtration rate (eGFR study visit and eGFR index ).
8 ACR measurements were used to define CKD albuminuria (CKD-A) stages; due to missing data of 99% of participants for ACR in the medical records, CKD-A stages could not be assessed for the hospital stay. CKD was also categorised as eGFR <60 vs !60 mL/min/1.73 m 2 . Changes in kidney function (ÁeGFR) between the index hospital stay and the study visit were calculated as eGFR index -eGFR study visit and categorised as declined (ÁeGFR <À5 mL/min/ 18 Determinants of CKD at the study visit and impaired kidney function during the index hospital stay were analysed by multivariate, multilevel logistic regression (including covariates that were significant in univariate analyses) using a backwards selection procedure and considering the participating country as a random intercept. Changes in eGFR between the index hospital stay and the study visit were investigated by multivariate, multilevel linear regression. In all of the multivariate models, no evidence for co-linearity between explanatory variables was evident, as tested for by variance inflation factors being >10. Analyses were performed using SAS 9.3 (SAS Institute, Inc., Cary, NC, USA). Two-sided p-values <0.05 were considered statistically significant. Table S1 ). In age-standardised data according to KDIGO classification (Figure 1 ; crude data in Supplementary Figure S2) , a further 12.9% of CHD patients presented with either major albuminuria (i.e. stages G1A3 0.8% and G2A3 1.9%) or moderately elevated albuminuria (i.e. stages G1A2 3.8% and G2A2 6.4%), despite a largely preserved eGFR (i.e. !60 mL/ min/1.73 m 2 ). Patients with CKD were significantly older, more likely to be female, with a longer history of CHD including CABG and PCI/stenting, and to present with a higher prevalence of classic CV risk factors and heart failure at the study visit (Table 1 ). In multivariate modelling, older age, female gender, prior CABG, history of congestive heart failure (CHF), diabetes and obesity were independently associated with the risk of CKD ( Table 2) .
Results
Prevalence
Prevalence of impaired kidney function during a hospital stay due to CHD (index)
Data on SCr index at hospital admission of the index CHD event were available in 92.3% (n ¼ 7380) patients. Subjects without SCr data reported a slightly longer duration of CHD prior to the index event (2.5 vs. 1.7 years, p ¼ 0.02), but did not differ from subjects with SCr index data regarding age, gender or the classification of the index event (all p > 0.2). The median eGFR index was 79.7 mL/min/1.73 m 2 (IQR 65.0-92.8 mL/min/ 1.73 m 2 ) and the median SCr index was 0.95 mg/dL (IQR 0.81-1.11 mg/dL). Impaired kidney function (i.e. eGFR index < 60 mL/min/1.73 m 2 ) was observed in 1266 patients (17.6%, age-standardised prevalence 16.9%). Among participating countries, age-standardised prevalences ranged from 7.5% in Finland to 38.2% in the UK (Supplementary Table S2 Patients with impaired kidney function at hospital admission presented with a longer duration of CHD and it was less likely that the index event was the primary diagnosis of CHD as compared to subjects with normal kidney function ( Table 3 ). The index event as the cause for hospital admission was more likely to be CABG and also planned as an elective intervention/surgery in renal patients. From multivariate modelling (Table 4) , older age, female gender, history of CABG and MI prior to the index event and history of CHF, along with diabetes and hypertension, were independent determinants of impaired kidney function at hospital admission.
Changes in kidney function between hospital stay (index) and study visit Table S3 ).
In multivariate linear regression modelling (Table 5 ), a positive ÁeGFR (i.e. improved kidney function between the index hospital stay and the study visit) was independently associated with older age, female gender, a longer time between the index hospital stay and the study visit, an index event representing a nonelective CHD procedure (particularly emergency events), a history of heart failure and better kidney function (i.e. higher eGFR) at hospital admission (see Supplementary Table S4 for patient characteristics at the index event according to changes in kidney function).
Discussion
The main finding in this large trans-European survey of patients with stable CHD is that approximately 17% of the patients have CKD with eGFR < 60 mL/min/ 1.73 m 2 . In addition, 12% were at increased risk of CKD progression, as indicated by significant albuminuria despite preserved eGFR. Age-standardised prevalences of CKD varied considerably between different countries. In addition to classic CV risk factors, a longer CHD duration and a history of CHF were independently associated with the risk of CKD. Impaired kidney function (i.e. chronic and/or acute reduction of eGFR) was common and indeed observed in approximately every fifth patient admitted for CHD. Dependent on the characteristics of the index CHD event, there was a substantial potential for recovery, but also for further decline of kidney function after hospital discharge.
Prevalence of CKD in stable CHD conditions at the EUROASPIRE IV study visit While CKD patients are at high risk of the development and progression of CHD, 9, 19 CKD is also an important risk factor for a worse clinical course in secondary CHD prevention. 4, 6 Reduced eGFR, as well as Self-reported or carbon monoxide in exhaled air >10 ppm. BMI: body mass index; CHD: coronary heart disease; CABG: coronary artery bypass graft; CV: cardiovascular; LDL: low-density lipoprotein; PCI: percutaneous coronary intervention; MI: myocardial infarction; JES: Joint European Societies; eGFR: estimated glomerular filtration rate; SCr: serum creatinine; ACR: urinary albumin creatinine ratio albuminuria/proteinuria, impact on the risk of CVD and CV events in CHD patients, 20, 21 but also in the general population. 10 The important role of albuminuria, in addition to reductions of eGFR, is reflected by the current KDIGO classification according to CKD-G and CKD-A stages. 8 Reports indicate that a lower eGFR is associated with a more than doubled risk of all-cause and CV mortality in those without significant proteinuria, yet those with largely preserved eGFR, but significant levels of albuminuria, experience an up to 3.7-fold higher risk of death (CV death 4.8-fold) when compared to patients without albuminuria. 10 As verified by the present survey, ACR is rarely measured in the clinical routine, and this particular group is frequently underdiagnosed, despite being at risk for progression of CKD 8 and for progression of CHD with limited evidence. 22, 23 We found approximately 12% of stable CHD patients to have largely preserved eGFR, but significant albuminuria. Unfortunately, it was impossible to address their risk for progression of CKD and CHD due to the lack of a second study visit.
The prevalences of CKD, usually defined as CKD stage 3a and higher (i.e. eGFR < 60 mL/min/1.73 m 2 ), 8 in a variety of settings, including population-based cohorts, are reported to be between 6% and 26%. 24 Yet, robust data on the proportion of CHD patients with CKD are limited. [25] [26] [27] Rigorous and standardised assessment of renal parameters in stable CHD patients across a broad variety of European countries is a major strength of the current EUROASPIRE IV study. The overall prevalence of CKD stages 3a and higher (i.e. eGFR < 60 mL/min/1.73 m 2 ) in the ambulatory and thus considerably stable setting was 17%, with wide variation between participating countries: low rates of approximately 13-14% were found in Finland, France, Ireland and Spain, and higher rates of up to 23-26% were found in Bosnia Herzegovina, Cyprus, Czech Republic and Slovenia. These differences might, on the one hand, be explained by variations in the study population due to a wide spectrum of recruitment success, 16 but may also reflect true variations in prevalence rates. 10, 24 The risk of CKD at the EUROASPIRE IV study visit was associated with older age, obesity, diabetes and female gender. The latter unexpected relationship might be due to under-representation and therefore potentially selective recruitment of female CHD patients in CHD studies per se, 28 and needs confirmation in future studies. CKD was more common in patients with a history of CABG, which might reflect a longer and more severe course of CHD. Cardiac surgery may also be causal of CKD because of potential episodes of AKI during cardiopulmonary bypass. 29, 30 CKD was also related to symptomatic CHF, which might reflect a two-way relationship and has been described as 'cardio-renal syndrome'; while cardiac dysfunction causes impaired kidney function (e.g. via reduced renal perfusion and several pathways including hormone activation), conversely, CKD itself can further aggravate CHD, particularly in established heart failure. 31, 32 Impaired kidney function in a hospital stay due to CHD Impaired kidney function has been identified as an important risk factor for complications during and worse outcome after hospital stays of various Body mass index !30 kg/m 2 at hospital admission or stated in discharge letter. CHD: coronary heart disease; CI: confidence interval; CV: cardiovascular; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; MI: myocardial infarction; CHD: congestive heart failure; SCr: serum creatinine; eGFR: estimated glomerular filtration.
causes, 33, 34 including CHD. 4, 30, 35 CKD patients frequently present with multiple comorbidities (older age, diabetes, vascular disease, etc.) and with CHD with a longer duration of CHD and potentially more severe coronary atherosclerosis. 9 For those undergoing CABG, CKD impacts on preoperative risk status according to EUROSCORE 2 assessment. 36 Moreover, this is a major determinant of post-operative AKI, 29 as well as in acute MI and after coronary interventions. 37, 38 It is increasingly acknowledged that even Based on first SCr measurement in patient record. CHD: coronary heart disease; CV: cardiovascular; CI: confidence interval; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; MI: myocardial infarction; AMI: acute myocardial infarction; STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST-elevation myocardial infarction; CHF: congestive heart failure; SCr: serum creatinine; eGFR: estimated glomerular filtration rate.
a slight deterioration of kidney function, reflected by a rise of SCr levels of 0.3 mg/dL, is associated with important early and long-term outcomes. 14, 29 EUROASPIRE IV collected the first recorded SCr measurement during the index event. Kidney function at hospital admission may be prone to variation due to acute clinical events; in particular, patients with acute coronary syndrome and MI may present with symptoms of acute heart failure (e.g. low cardiac output), which may result in episodes of AKI. In addition, CABG and contrast application during PCI may cause impairments in kidney function. Therefore we report on impaired kidney function during the hospital stay rather than CKD, as we cannot claim a chronic and stable condition in all patients. Approximately 17% of the patients had impaired kidney function, however, with major variations between countries (from 10% to >30%). Although this might at least partly reflect varying recruitment strategies, 16 it would be of great interest and importance to investigate whether these differences reflect true variations at the patient level across European countries, or whether hospital admission and transfer strategies between different healthcare systems or variations in CHD treatment and care are responsible for these dramatic prevalence differences. Older age, female gender, diabetes and hypertension were independently related to impaired kidney function at hospital admission, as were also previous CABG or MI and a history of CHF. This reflects a more severe course of CHD and the specific relationship of the 'cardio-renal syndrome'. 31 Apart from female gender, which needs further investigation (see above), these determinants describe CHD patients with CKD as individuals with a multitude of comorbidities.
Changes of kidney function after a hospital stay due to CHD There are few data available on the course of CKD in the ambulatory setting after a hospital stay due to CHD. 30, [39] [40] [41] In situations of 'true' CKD that is already present prior to the hospital stay, it is unlikely that major improvements in kidney function can be achieved. The aim of care must then focus on reducing the decline in kidney function by renin-angiotensinaldosterone-system (RAAS) blockade, avoidance of nephrotoxic agents and strict control of classic CV risk factors. 8 In contrast, those CHD patients with an episode of AKI during the hospital stay but without major pre-existing CKD have a great potential for improvements or complete recovery of kidney function. However, even those patients with markers of kidney function in the normal range after AKI remain at risk for the development of CKD, whereas other patients are at risk for non-recovery of AKI and either experience a rapid decline in kidney function or remain dependent on renal replacement therapy. 14 In EUROASPIRE IV, we report on the proportions of those with declined, stable and improved kidney function, but due to the limitations discussed below (data on episodes of AKI during the index hospital stay not being captured in the dataset, as well as data on kidney function at hospital discharge, varying methods of SCr measurement at index hospital stay, confounding by medical treatment, lifestyle changes, etc., between index hospital stay and EUROASPIRE IV study visit), our results should be interpreted with caution as purely descriptive and hypothesis generating. Patients with better kidney function at hospital admission were more likely to present with improved kidney function at the study visit, as well as female patients and those with a longer duration between the index event and the study visit. Those patients in whom the index event was classified as non-elective had a greater chance of recovery of kidney function as compared to those with elective procedures. This might be explained by the fact that CKD patients undergo elective procedures mostly in stable conditions and thus there might be no reason for meaningful improvements of kidney function thereafter. Yet, older patients and those with CHF also recovered kidney function, which may initially seem counterintuitive. This may, however, be an expression of greater awareness and more intense physician care after hospital discharge.
Strengths and limitations
The EUROASPIRE IV dataset contains high-quality prospectively collected data of the study visit, including standardised measurements of the risk factors of a large sample of CHD patients across 24 European countries and is thus a unique source for describing CKD and its associated factors, particularly as there were few missing data on ACR as well as on SCr. However, there are limitations. First, the prevalence rates cannot be considered as representative of the participating countries due to the selection processes of the centres, the recruitment success within the countries and the fact that only those patients who survived long enough after the index hospital stay could be enrolled in EUROASPIRE IV. Therefore, it is possible that the study participants may represent a considerably 'healthier' CHD population, as 'sicker' CHD patients may have died early, may not have been able to attend the study visit due to medical/physical circumstances or may have opted not to participate in a study dedicated to the quality of secondary prevention in CHD. 16 Second, the validity of retrospectively collected data of hospital records in 78 of the centres might be limited due to variation in SCr measurement methods in routine patient care and the non-standardised description of risk factors and completeness at admission and in discharge letters. In addition, ACR was not routinely measured in European hospitals for analysing the level of proteinuria and variations among countries. Third, we were not able to address all of the factors related to changes in eGFR between discharge of the index hospital stay, including episodes of AKI, fluid management, kidney function at hospital discharge, medical care (e.g. the use of angiotensin-converting enzyme inhibitors and diuretics) and patient compliance/behaviour in the ambulatory setting. Detailed analysis of these factors would be beyond the scope of this manuscript, and we therefore included only determinants in our models that were available during the hospital stay describing their prognostic value regarding changes in kidney function. Finally, the robust and consistent association of female gender with impaired kidney function at the study visit as well as during the index hospital stay needs to be interpreted with caution. As discussed above, underrepresentation and selective recruitment of women might have influenced the results.
Conclusion
The EUROASPIRE IV dataset provides a comprehensive, up-to-date view of kidney function in CHD patients across Europe. In CHD patients with stable conditions, every forth to fifth patient has CKD, including those with preserved eGFR but significant albuminuria. As CKD is common in hospital stays for CHD, routine albuminuria measurement might be useful for determining the entire risk spectrum of CKD, including AKI. The present findings underline the importance of identifying patients who are at high risk of developing CKD in order to counteract such progression.
